A New King of The GLP-1s Could Be Crowned – Cardiac Wire
A New King of The GLP-1s Could Be Crowned Cardiac Wire‘Godzilla’ of weight-loss drugs could provide other important health…
Ozempic Rival Retatrutide Delivers 25% Weight Loss In Phase 3 Trial
An experimental weight-loss injection has helped people with obesity lose an average of up to 25 per cent…
Eli Lilly, NIH grants, Novartis, Regeneron: Readout Newsletter
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter…
Doctors condemn Eli Lilly move to dispense GLP-1 medication Mounjaro direct to door
A move by a multi-billion-dollar global pharmaceutical company to bypass bricks and mortar pharmacies and deliver its GLP-1…
Hundreds of lawsuits allege GLP-1s like Ozempic, Wegovy, Mounjaro caused vision loss
PHOENIX (AZFamily/Gray News) — Hundreds of lawsuits have been filed against major GLP-1 makers Eli Lilly and Novo…
Hundreds of lawsuits filed against some GLP-1 Makers over vision loss
Hundreds of Americans are suing GLP-1 drugmakers Novo Nordisk and Ely Lilly, saying they were not adequately warned…
Novo Sets Long-Term Targets Ahead of Semaglutide Patent Expirations – Yahoo Finance
Novo Sets Long-Term Targets Ahead of Semaglutide Patent Expirations Yahoo FinanceNovo shares slide as drugmaker lays out post-Wegovy growth…
AbbVie vs. Eli Lilly and: Which Healthcare Stock Is a Better Buy in 2026?
The pharmaceutical market is currently defined by a race to replace aging blockbusters with next-generation therapies. Deciding whether…
Eli Lilly’s (LLY) Growth Story Keeps Adding Chapters
On August 5, Eli Lilly (NYSE:LLY) told investors its second quarter delivered 48% revenue growth, and the days…
Eli Lilly CEO still wants deal to bring Mounjaro to Australia under PBS
Eli Lilly pharmaceuticals CEO David Ricks says he still wants to reach an agreement with the Australian government…
Semaglutide Generics Surge in Sales Despite Supply Challenges, ETPharma
New Delhi: After a brief slowdown, sales of generic versions of the weight-loss drug semaglutide recorded a strong…
Will Mounjaro & Zepbound Drive Lilly’s Q2 Results: Buy, Sell or Hold?
Eli Lilly and Company LLY will report its second-quarter 2026 earnings on Aug. 5, before market open. The Zacks…